← Back to Screener
SAB Biotherapeutics, Inc. Warrant (SABSW)
Price$0.02
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-61.43%
Price vs S&P 500 (4W)2.98%
VGM Score7.55
All Metrics
Price vs S&P 500 (YTD)-56.40%
10-Day Avg Trading Volume0.02M
3-Month Avg Trading Volume0.02M
52-Week High$0.18
26-Week Price Return-50.46%
13-Week Price Return-57.11%
3-Month Return Std Dev228.63%
Year-to-Date Return-47.76%
5-Day Price Return-17.26%
Month-to-Date Return6.54%
Price vs S&P 500 (13W)-65.26%
Beta-0.11x
52-Week Low$0.01
mGradeF
vgmGradeF
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SABSWSAB Biotherapeutics, Inc. Warrant | — | — | F | $0.02 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted human polyclonal antibodies using its proprietary DiversitAb platform. The company uses genetically modified cattle to produce human antibodies without relying on human plasma or serum, offering a differentiated manufacturing approach. This technology enables rapid production of high-volume therapeutic antibodies, potentially providing a competitive advantage in immunotherapy development.